首页> 外文期刊>European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology >Enhanced clinical utility of the NucliSens EasyQ RSV A+B Assay for rapid detection of respiratory syncytial virus in clinical samples.
【24h】

Enhanced clinical utility of the NucliSens EasyQ RSV A+B Assay for rapid detection of respiratory syncytial virus in clinical samples.

机译:NucliSens EasyQ RSV A + B分析的增强的临床实用性,可快速检测临床样品中的呼吸道合胞病毒。

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of the present study was to compare traditional methods for the detection of respiratory syncytial virus with a newly developed commercial assay based on real-time nucleic acid sequence based amplification. Respiratory syncytial virus is a major cause of severe respiratory infection in infants and in certain groups of older children and adults. Treatment options are limited, but a rapid diagnosis improves patient management and infection control. The rapid diagnosis of respiratory syncytial virus currently relies on antigen detection assays. These tests are limited to use in certain good-quality types of samples, which are rarely obtained from adult patients. Molecular-based assays for the detection of respiratory syncytial virus are shown to be highly sensitive, specific, and more rapid than cell culture techniques. This retrospective study compared traditional laboratory techniques for the detection of respiratory syncytial virus in 508 respiratory samples collected during the winter months of 2003-2004 against the recently developed, commercially available NucliSens EasyQ Respiratory Syncytial Virus A+B assay (bioMerieux, Marcy l'Etoile, France), which is based on real-time nucleic acid sequence based amplification using molecular beacons and an internal control. Using traditional techniques, the prevalence of respiratory syncytial virus in the samples tested was found to be 21%. Using the real-time nucleic acid sequence-based amplification assay, an additional 41 samples from patients with a clinically diagnosed respiratory illness were found to be positive for respiratory syncytial virus. The NucliSens EasyQ assay was shown to be sensitive and specific for the detection of respiratory syncytial virus A+B in different types of respiratory samples. Moreover, the time required to complete the assay was <4 h, so results could be obtained on the same day as sample receipt in the laboratory.
机译:本研究的目的是将检测呼吸道合胞病毒的传统方法与基于基于实时核酸序列的扩增的新开发的商业检测方法进行比较。呼吸道合胞病毒是婴儿以及某些年龄较大的儿童和成人中严重呼吸道感染的主要原因。治疗选择有限,但是快速诊断可以改善患者管理和感染控制。呼吸道合胞病毒的快速诊断当前依赖于抗原检测测定。这些测试仅限于某些高质量类型的样本,而这些样本很少从成年患者那里获得。与呼吸道合胞病毒相比,用于检测呼吸道合胞病毒的基于分子的检测方法具有更高的灵敏度,特异性和更快性。这项回顾性研究将用于检测2003年至2004年冬季的508个呼吸道样本中的呼吸道合胞病毒的传统实验室技术与最近开发的可商购的NucliSens EasyQ呼吸道合胞病毒A + B检测法(bioMerieux,Marcy l'Etoile (法国),它基于使用分子信标和内部对照的基于实时核酸序列的扩增。使用传统技术,发现被测样品中呼吸道合胞病毒的流行率为21%。使用基于实时核酸序列的扩增测定法,从临床诊断为呼吸系统疾病的患者中又发现41个样本对呼吸道合胞病毒呈阳性反应。已显示NucliSens EasyQ测定法对检测不同类型呼吸道样本中的呼吸道合胞病毒A + B灵敏且特异。此外,完成测定所需的时间小于4小时,因此可以在实验室中与样品接收的同一天获得结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号